Regarding the top-level design of AI+healthcare development, significant measures will be taken at the policy level. Recently, seven departments including the Ministry of Industry and Information Technology, the Ministry of Commerce, the National Health Commission, the National Medical Insurance Administration, the National Data Bureau, the National Administration of Traditional Chinese Medicine, and the National Medical Products Administration jointly released the "Implementation Plan for the Digital Transformation of the Pharmaceutical Industry (2025-2030)" (hereinafter referred to as the "Implementation Plan"), which clarifies that digital transformation is an important path for the pharmaceutical industry to achieve high-quality development, aiming to drive the upgrading of the entire industry chain through technologies such as artificial intelligence and big data, and promote the high-end, intelligent, green, and integrated development of the industry. Against the backdrop of accelerated iteration of global pharmaceutical technology and intensified industry competition, the traditional pharmaceutical industry is facing pain points such as long research and development cycles, high production costs, and insufficient supply chain resilience. Artificial intelligence and other digital technologies provide core driving force for the transformation and upgrading of the pharmaceutical industry by breaking through research and development bottlenecks, optimizing production processes and circulation systems, and becoming a key support for achieving high-quality development. It is worth noting that, relying on the "AI+H2H (Hospital to Home from hospital to home) new smart medical ecosystem", "the first unit of AI chronic disease management", Fang Zhou Jianke (06086. HK) has verified the core value of digital intelligence in improving medical service accessibility and patient experience through AI technology to enable chronic disease management, physician assistance and precision services, and has provided a practical sample of digital intelligence transformation for the Internet medical industry. In recent years, the government has successively issued multiple policy documents such as the "14th Five Year Plan" for the development of the pharmaceutical industry, the "Action Plan for High Quality Development of the Pharmaceutical Industry (2023-2025)," the "Action Plan for Digital Transformation of Manufacturing Industry," and the "Opinions on Deepening the Reform of Drug and Medical Device Supervision to Promote High Quality Development of the Pharmaceutical Industry," providing systematic support for the digital transformation of the pharmaceutical industry. This implementation plan further refines the entire chain transformation path, accelerates the landing of technology and industrial integration. At the same time, the Implementation Plan proposes two development goals: by 2027, significant progress will be made in the digital transformation of the pharmaceutical industry, and the competitiveness of the entire pharmaceutical industry chain driven by digital technology and the level of quality management throughout the entire lifecycle will be significantly improved. By 2030, large-scale pharmaceutical industry enterprises will basically achieve full coverage of digital transformation, significantly improve their ability to integrate and innovate digital technology, further improve the data system of the entire pharmaceutical industry chain, and further enhance the ecological system of digital transformation in the pharmaceutical industry. According to a research report by Wanlian Securities, the digital transformation is the core path to breaking through the problems of low research and development efficiency, high costs, insufficient production intelligence level, and weak supply chain collaboration in China's pharmaceutical industry. The release of the Implementation Plan further accelerates the promotion and application of digital and intelligent technologies in the pharmaceutical industry, and the integration of new generation information technology represented by artificial intelligence with pharmaceutical research and development is increasingly deepening. According to a research report by CITIC Securities, the "Plan" has a high design position, wide coverage, and strong support, and the implementation effect of digitalization in the pharmaceutical industry is expected. Among them, policy guidance to integrate and release the value of medical data elements is expected to empower the development of the healthcare industry. The full chain transmission of digitalization in the pharmaceutical industry benefits various links in the pharmaceutical industry chain, including ① pharmaceutical industry research and development and production, ② artificial intelligence tool providers, and ③ pharmaceutical industry information infrastructure construction. At present, the digital transformation of the pharmaceutical industry has made progress and breakthroughs in multiple fields: in terms of research and development, AI target screening, gene and clinical data fusion, and virtual experiments have significantly shortened the research and development cycle; In terms of production, the digital workshop achieves real-time and precise control of process parameters, and the intelligent traceability system covers the entire lifecycle of drugs; In terms of circulation, intelligent logistics and blockchain traceability systems enhance supply chain resilience. At the same time, AI technology has also been widely applied in pharmaceutical service scenarios. Through technological breakthroughs and scenario innovation, it is reshaping the full cycle mode of health management, providing new solutions for problems such as differences in primary healthcare resource allocation, weak service capabilities, data silos, and poor patient compliance. Breakthrough practices have emerged in the deep application of AI technology in pharmaceutical service scenarios. Taking Fangzhou Jianke as an example, it is driven by AI, big data, and cloud computing technologies, and continuously innovates the chronic disease management service model through technological innovation. In 2024, the platform will implement a comprehensive strategic upgrade to its first "H2H Smart Medical New Ecological Innovation Platform", creating an "AI+H2H Smart Medical New Ecological System" that integrates specialization, intelligence, and efficiency, highlighting the core value of AI in improving medical service accessibility and optimizing patient experience through personalized health management processes. The deployment of the four major action plans for transformation tasks, the creation of benchmark scenarios, and the guidance and guarantee of industry sample policies are the solid foundation for the digital transformation of the pharmaceutical industry. The Implementation Plan deploys 14 key tasks around the four core actions to systematically promote the digital transformation of the pharmaceutical industry. One is the action of empowering digital intelligence technology, strengthening the research and application of digital intelligence products in the pharmaceutical industry, integrating and releasing the value of pharmaceutical data elements, transforming and upgrading information infrastructure, and deepening the application of artificial intelligence empowerment. The second is the promotion action of digital transformation, which aims to promote excellent scenarios of typical digital technology applications, cultivate outstanding enterprises in digital transformation, and build a digital pharmaceutical industry park. The third is the action of building a digital service system, strengthening standard guidance, enhancing quality support, cultivating innovative carriers, and strengthening service teams. The fourth is the action to enhance smart supervision, explore new models of smart supervision, innovate new tools for smart supervision, and research new methods for smart supervision. The Implementation Plan emphasizes promoting the digital transformation of the industry by integrating medical data elements and deepening the application of artificial intelligence. By jointly building a data platform to activate the circulation of data elements, providing precise support for research and development, production, and clinical practice, promoting resource sharing and efficient utilization, and assisting innovation and scientific decision-making; At the same time, relying on the pharmaceutical big model innovation platform, accelerate the integration and application of AI technology in the entire industry chain, form benchmark scenarios, promote the construction of a safe and controllable pharmaceutical industry ecosystem, and provide core driving force for high-quality development. As mentioned in the "Implementation Plan" regarding "deepening the application of artificial intelligence empowerment", pilot projects will be launched to empower the entire pharmaceutical industry chain with artificial intelligence, encouraging leading pharmaceutical companies to form alliances with medical institutions, research institutes, upstream and downstream enterprises, large users, etc., to form a number of landmark application scenarios with significant effects for the entire pharmaceutical industry chain. As a leading benchmark enterprise in the Internet medical field, Ark Healthcare deeply practices the landing application of digital and intelligent technologies in the industry. It uses AI to analyze consumer habits to accurately reach potential users, empower digital marketing and partner brand building, and rely on professional services such as health science popularization content matrix and remote medication guidance to enhance user stickiness. The intelligent service capability built on the foundation of AI technology effectively empowers upstream and downstream enterprises to collaborate and provide full chain digital solutions for the industry. Fangzhou Jianke has built a typical example of the digital transformation of medicine with the core of the "AI+H2H Smart Medical New Ecological Innovation Platform". Its data governance capabilities have been recognized by authorities: in 2024, it passed the DCMM (Data Management Capability Maturity) certification of the China Electronic Information Industry Federation and was awarded the title of "Guangzhou Data Governance Demonstration Enterprise". In terms of AI applications, Fangzhou Jianke's independently developed "AI+Medical Intelligent Agent Matrix" deeply integrates "intelligent agents+scenarios", achieving 7 × 24 hours of primary consultation response through AI doctor assistants, and assisting doctors in decision-making through structured processing of symptoms, medical history, and examination data; AI customer service assistants optimize service efficiency and quality through real-time speech suggestions; AI creative assistant automatically generates precise popular science content, expanding the coverage of health knowledge. The intelligent agent matrix is empowered by full process AI technology, accurately matching the requirements of the "full industry chain application pilot", becoming a benchmark scenario for "AI empowering the entire pharmaceutical industry chain", verifying the significant value of digital transformation in improving service efficiency and optimizing resource allocation, and providing a replicable practical path for the industry. At the critical stage of digital transformation in the pharmaceutical industry, although the industry has made significant progress, it still needs to face the complex situation of challenges and opportunities coexisting. The promotion of the Implementation Plan will deepen the integration of artificial intelligence and the industrial chain. With the dual empowerment of policies and technology, digitization will not only reshape the ecology of the pharmaceutical industry, but also build sustainable innovation support for public health, opening up a new pattern of high-quality development. (New Society)